

Colon Case Study

onco*type* DX[®]
Colon Cancer Assay

52-Year-Old Female Patient

Tumor Type Adenocarcinoma

Tumor Stage Stage III A/B (N1-3)

Histologic Grade Low (1)

Lymph Node Status Negative

Number of Lymph Nodes Assessed 2

Mismatch Repair (MMR) Status MMR-P (MSS)

Lymphovascular Invasion Present

Perforation Absent

Obstruction Absent

Other Information Lymph node status was negative, but extra nodal tumor deposits: N1c

Patient received two doses of 5-FU Oxaliplatin, but Oxaliplatin was stopped when the patient showed neuropathy and other signs of intolerable toxicity. The patient is continuing with capecitabine only.

CASE SUBMITTED BY:

Frederic A. Slezak MD MBA

Summa Health System

Akron OH

Colon Case Study

CLINICAL EXPERIENCE


Recurrence Score = 0



Prognosis for Stage III A/B Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSAPB C-07 trial which randomized 409 stage III A/B patients to 5FU/LV versus 5FU/LV+oxaliplatin.¹

The average 5 year risk of recurrence for patients who had a Recurrence Score[®] result of 0 was:



Other Considerations: The recurrence risk for patients with ≥ 12 nodes examined was lower than the risk for those with < 12 nodes examined.

References:

1. Yothers et al. J Clin Oncol. 2013.